Peter Llewellyn-Davies
Director/Board Member at SHIELD THERAPEUTICS PLC
Net worth: 3 006 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hans-Peter Hasler | M | 68 | 6 years | |
| Hansjörg Plaggemars | M | 53 | 5 years | |
| Jackie Mitchell | M | - | 12 years | |
| Christian Schweiger | M | 57 | 16 years | |
| Dolores Schendel | M | - | 10 years | |
| Alexander Link | M | 53 | 4 years | |
| David Childs | M | - | 13 years | |
| Gregory Madison | M | 57 | 3 years | |
| Andreas Pahl | M | - | 12 years | |
| Karl Lundström | M | 62 | 3 years | |
| Lucy Huntington-Bailey | F | - | 9 years | |
| Christof Hettich | M | 64 | 14 years | |
| Maria Lacerca-Allen | M | 57 | 3 years | |
| Paul Spoors | M | - | 5 years | |
| Karen Chandler Smith | F | - | - | |
| Edward Charles | M | - |
APEIRON Biologics AG
 APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 4 years |
| Andreas Gerber | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 years |
| Erwin Rasinger | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
| Helmut Schühsler | M | 65 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
| Rainer Herschlein | M | - | 3 years | |
| Andy Hurley | M | - | 1 years | |
| Eva Katheder | F | - | 3 years | |
| Manfred Reichl | M | 71 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 17 years |
| Birgit Kudlek | M | 57 | 12 years | |
| Ulrich Granzer | M | 63 |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 3 years |
| Santosh Shanbhag | M | 47 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tim Watts | M | 66 | 3 years | |
| Richard Jones | M | 58 | 7 years | |
| Carl Sterritt | M | 55 | 12 years | |
| Joanne Elizabeth Estell | F | 53 | - | |
| Angela Hildreth | F | - | 6 years | |
| James Karis | M | 76 | 4 years | |
| María del Pilar de la Huerta Martínez | F | 55 | 8 years | |
| Charlotte Lohmann | F | 54 | 11 years | |
| David Lemus | M | 61 | 1 years | |
| Markus Dangl | M | - | - | |
| Jan Schmidt-Brand | M | - | 12 years | |
| Heikki Lanckriet | M | 46 | 4 years | |
| Frank Mathias | M | 62 | 13 years | |
| Josef Penninger | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | 16 years |
| Joseph Fernández | M | 64 | 9 years | |
| Rolf K. Hoffmann | M | 64 | 3 years | |
| Karl Keegan | M | 57 | 1 years | |
| Andrew Heath | M | 76 | 2 years | |
| Thomas Werner | M | 68 | 3 years | |
| Mark Sampson | M | - | 5 years | |
| Paul Steckler | M | - | - | |
| Rainer C. Burian | M | - |
APEIRON Biologics AG
APEIRON Biologics AG BiotechnologyHealth Technology APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria. | - |
| Jose Menoyo | M | - | 2 years | |
| Iris Löw-Friedrich | M | 63 | - | |
| Mathias Albert Boehringer | M | - | 5 years | |
| Tim McCarthy McCarthy | M | 68 | 4 years | |
| Norbert Riedel | M | 66 | 10 years | |
| David Ebsworth | M | 69 | - | |
| David John Roth | M | 56 | 3 years | |
| Pol Bamelis | M | 85 | 12 years | |
| Thomas Borcholte | M | - | 6 years | |
| Alexandra Goll | M | 68 | 6 years | |
| Olav Zilian | M | - | 1 years | |
| Trevor Jarman | M | 76 | 4 years | |
| Klaus Kühn | M | 72 | 2 years | |
| Kai Pinkernell | M | - | - | |
| Rudiger Hauffe | M | - | - | |
| Yi Ta Li | M | - | - | |
| Cristina Garmendia Mendizábal | M | - | 7 years | |
| Andreas Krebs | M | 65 | 6 years | |
| Martin Bürmann | M | 55 | - | |
| Hans-Peter Rudolf | M | 58 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Germany | 35 | 51.47% |
| United Kingdom | 25 | 36.76% |
| Austria | 8 | 11.76% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Peter Llewellyn-Davies
- Personal Network
